Page 30 - Nsclc News Today

Shared insight on the use of first-generation EGFR tyrosine kinase inhibitors and the role of immunotherapy in treating patients with NSCLC with uncommon EGFR mutations.

Julie R. Brahmer, MD, discusses treatment considerations when choosing between afatinib and osimertinib in patients with NSCLC with rare EGFR mutations.

James Chih-Hsin Yang, MD, PhD, discusses the implications of the phase 3 KEYNOTE-789 trial and what directions investigators can examine in the future to help fill the unmet need for patients with TKI-resistant, EGFR-mutated metastatic non–small cell lung cancer.

Combination treatment with atezolizumab, carboplatin, and pemetrexed showed activity in patients with advanced nonsquamous non–small cell lung cancer and untreated brain metastases without neurologic symptoms or asymptomatic with medical treatment.

Emerging data continue to shape perioperative therapy decisions for patients with early-stage non–small cell lung cancer.

A brief review of the role that immunotherapy agents play in the frontline management of patients with small cell lung cancer.

Nicholas Coupe, MBBS, PhD, discusses the rationale for investigating IMM60 with pembrolizumab in patients with advanced melanoma or metastatic non-small cell lung cancer, as well as key background information that led to this investigation.

Experts on non–small cell lung cancer discuss strategies to improve molecular testing and opportunities for community physicians to reach out to expert oncologists for clinical insights.

Key opinion leaders on non–small cell lung cancer review treatment options for patients with EGFR mutations.

Martin Wermke, MD, discusses why the novel T-cell engager BI 764532 may serve as a promising treatment option targeting DLL3 in small cell lung cancer and neuroendocrine carcinomas .